Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD

Ann Intern Med. 2021 Jan;174(1):JC10. doi: 10.7326/ACPJ202101190-010. Epub 2021 Jan 5.

Authors

Qiukui Hao¹, Gordon Guyatt²

Affiliations

¹ The Center of Gerontology and Geriatrics/National Clinical Research Center for Geriatrics West China Hospital, Sichuan University, Chengdu, Sichuan, China (Q.H.).
² McMaster University, Hamilton, Ontario, Canada (G.G.).

PMID: 33395336
DOI: 10.7326/ACPJ202101190-010

Abstract

Bonaca MP, Wiviott SD, Zelniker TA, et al. Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58. Circulation. 2020;142:734-47. 32795086.

Publication types

Comment

MeSH terms

Benzhydryl Compounds
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucosides
Humans
Kidney
Peripheral Arterial Disease* / drug therapy
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

Benzhydryl Compounds
Glucosides
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin